Activating mutations of TOR (target of rapamycin)

Genes to Cells

Volumn 16, Issue 2, 2011, Pages 141-151

  Hardt, Molly ^a   Chantaravisoot, Naphat ^a   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVE SITE; EUKARYOTIC CELL; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN GENOME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; GENE EXPRESSION PROFILING; HUMANS; MICE; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EUKARYOTA; MAMMALIA;

EID: 78751699575     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/j.1365-2443.2010.01482.x     Document Type: Article

References (49)

1. Abraham, R.T. (2004) PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 3, 883-887.
2. Aspuria, P.J., Sato, T. & Tamanoi, F. (2007) The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell Cycle 6, 1692-1695.
3. Bosotti, R., Isacchi, A. & Sonnhammer, E.L. (2000) FAT: a novel domain in PIK-related kinases. Trends Biochem. Sci. 25, 225-227.
4. Brunn, G.J., Fadden, P., Haystead, T.A. & Lawrence, J.C. Jr (1997) The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J. Biol. Chem. 272, 32547-32550.
5. Dunlop, E.A., Dodd, K.M., Seymour, L.A. & Tee, A.R. (2009) Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell. Signal. 21, 1073-1084.
6. Edinger, A.L. & Thompson, C.B. (2004) An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23, 5654-5663.
7. Gymnopoulos, M., Elsliger, M.A. & Vogt, P.K. (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104, 5569-5574.
8. Hall, M.N. & Tamanoi, F., eds (2010) The enzymes: Structure, function and regulation of TOR complexes from yeasts to mammals, vol. 27, part A. Amsterdam: Academic Press/Elsevier.
9. Huang, J. & Manning, B.D. (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222.
10. Inoki, K. & Guan, K.L. (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum. Mol. Genet. 18, R94-R100.
11. Inoki, K., Zhu, T. & Guan, K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590.
12. Jacinto, E., Loewith, R., Shmidt, A., Lin, S., Ruegg, M.A. & Hall, M.N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128.
13. Karbowniczek, M., Spittle, C.S., Morrison, T., Wu, H. & Henske, E.P. (2008) mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol. 128, 980-987.
14. Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T.P. & Guan, K.L. (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10, 935-945.
15. Knutson, B.A. (2010) Insights into the domain and repeat architecture of target of rapamycin. J. Struct. Biol. 170, 354-363.
16. Kwiatkowski, D.J. & Manning, B.D. (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14 Spec No. 2: R251-R258.
17. Laplante, M. & Sabatini, D.M. (2009) mTOR signaling at a glance. J. Cell Sci. 122, 3589-3594.
18. Lempiainen, H. & Halazonetis, T.D. (2009) Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 28, 3067-3073.
19. Lochhead, P.A. (2009) Protein kinase activation loop autophosphorylation in cis: overcoming a Catch-22 situation. Sci. Signal. 2, pe4.
20. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. & Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702-713.
21. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. & Cantley, L.C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10, 151-162.
22. Miled, N., Yan, Y., Hon, W.C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H.J., Backer, J.M. & Williams, R.L. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242.
23. Molinolo, A.A., Hewitt, S.M., Amornphimoltham, P., et al. (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin. Cancer Res. 13, 4964-4973.
24. Nakashima, A., Sato, T. & Tamanoi, F. (2010) Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. J. Cell Sci. 123(Pt 5), 777-786.
25. Nobukuni, T., Kozma, S.C. & Thomas, G. (2007) hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. Curr. Opin. Cell Biol. 19, 135-141.
26. Ohne, Y., Takahara, T., Hatakeyama, R., Matsuzaki, T., Noda, M., Mizushima, N. & Maeda, T. (2008) Isolation of hyperactive mutants of mammalian target of rapamycin. J. Biol. Chem. 283, 31861-31870.
27. Pacold, M.E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C.T., Walker, E.H., Hawkins, P.T., Stephens, L., Eccleston, J.F. & Williams, R.L. (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931-943.
28. Polak, P. & Hall, M.N. (2009) mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 21, 209-218.
29. Reinke, A., Chen, J.C., Aronova, S. & Powers, T. (2006) Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. J. Biol. Chem. 281, 31616-31626.
30. Robb, V.A., Karbowniczek, M., Klein-Szanto, A.J. & Henske, E.P. (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177, 346-352.
31. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B. & Velculescu, V.E. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
32. Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L. & Sabatini, D.M. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501.
33. Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A. & Sabatini, D.M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915.
34. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P. & Sabatini, D.M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302.
35. Sato, T., Nakashima, A., Guo, L., Coffman, K. & Tamanoi, F. (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29, 2746-2752.
36. Sato, T., Nakashima, A., Guo, L. & Tamanoi, F. (2009) Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol. Chem. 284, 12783-12791.
37. Sekulic, A., Hudson, C.C., Homme, J.L., Yin, P., Otterness, D.M., Karnitz, L.M. & Abraham, R.T. (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60, 3504-3513.
38. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A. & Cantley, L.C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
39. Sturgill, T.W. & Hall, M.N. (2009) Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem. Biol. 4, 999-1015.
40. Takahara, T., Hara, K., Yonezawa, K., Sorimachi, H. & Maeda, T. (2006) Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J. Biol. Chem. 281, 28605-28614.
41. Tamanoi, F. & Hall, M.N., eds (2010) The enzymes: Structure, function and regulation of TOR complexes from yeasts to mammals, vol. 28, part B. Amsterdam: Academic Press/Elsevier.
42. Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M. & Tamanoi, F. (2007) Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl Acad. Sci. USA 104, 3514-3519.
43. Veverka, V., Crabbe, T., Bird, I., Lennie, G., Muskett, F.W., Taylor, R.J. & Carr, M.D. (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27, 585-595.
44. Vogt, P.K., Kang, S., Elsliger, M.A. & Gymnopoulos, M. (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32, 342-349.
45. Wang, L., Rhodes, C.J. & Lawrence, J.C. Jr (2006) Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J. Biol. Chem. 281, 24293-24303.
46. Wullschleger, S., Loewith, R. & Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484.
47. Yan, L., Mieulet, V., Burgess, D., Findlay, G.M., Sully, K., Procter, J., Goris, J., Janssens, V., Morrice, N.A. & Lamb, R.F. (2010) PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. Mol. Cell 37, 633-642.
48. Zhao, L. & Vogt, P.K. (2008) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652-2657.
49. Zhao, L. & Vogt, P.K. (2009) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9, 596-600.